维京药店的肥胖药物试验由于安全考虑而停止,但仍被视为获取目标。 Viking Therapeutics' obesity drug trial halted due to safety concerns, yet still seen as acquisition target.

维京治疗公司因安全性和耐受性问题而面临VK2735抗肥胖药物第二阶段试验的挫折,导致20%的药物停用率. Viking Therapeutics faced a setback with its phase 2 trial for the anti-obesity drug VK2735 due to safety and tolerability issues, causing a 20% discontinuation rate. 尽管如此,该公司仍可吸引大型制药公司对合伙关系或收购的兴趣,这可能导致该药物的进一步发展。 Despite this, the company could still attract interest from larger pharmaceutical firms for partnerships or acquisitions, which could lead to further development of the drug. 这表明,尽管最近面临种种挑战,但仍有增长潜力。 This suggests potential for growth despite the recent challenges.